Erlanger Health System is one of 6 hospitals in the United States participating in a clinical trial of a novel device called the Ischemic Stroke System (ISS) that may greatly increase the window of treatment for stroke victims. Current treatments allow for a maximum of 8–9 hours before irreversible tissue loss occurs. The ISS treatment would extend that window to 24 hours.